Small-Molecule Inhibition of UBE2T/FANCL-Mediated Ubiquitylation in the Fanconi Anemia Pathway

Area of Science:

• Molecular Biology
• Cancer Research
• DNA Repair Mechanisms

Background:

• The Fanconi anemia (FA) pathway is crucial for repairing DNA interstrand cross-links and replication fork stalling.
• Monoubiquitylation of the FANCD2-FANCI complex by UBE2T and FANCL is a key step in the FA pathway.
• The FA pathway's activation correlates with chemotherapy resistance in various cancers, making it a potential therapeutic target.

Purpose of the Study:

• To identify selective inhibitors of ubiquitin conjugation pathways, specifically targeting the FA pathway.
• To find small molecules that can overcome chemotherapy resistance mediated by the FA pathway.

Main Methods:

• A high-throughput screening assay was developed to identify inhibitors of UBE2T/FANCL-mediated FANCD2 monoubiquitylation.
• The identified inhibitor's efficacy in sensitizing cells to DNA cross-linking agents was evaluated.

Main Results:

• A novel small-molecule inhibitor targeting UBE2T/FANCL-mediated FANCD2 monoubiquitylation was discovered.
• This inhibitor demonstrated the ability to sensitize cells to carboplatin, a DNA cross-linking chemotherapy agent.

Conclusions:

• The identified small molecule is a potent inhibitor of a critical step in the Fanconi anemia pathway.
• This finding provides a promising therapeutic lead for overcoming carboplatin resistance in cancers associated with FA pathway activation.